MLYS

$24.07+0.79 (+3.39%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$24.07
Potential Upside
5%
Whystock Fair Value$25.27
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, or...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-29.73%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
25.50

Recent News

Simply Wall St.
Mar 20, 2026

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?

Wondering if Mineralys Therapeutics at a last close of US$23.28 still offers value, or if most of the easy gains are already behind it. The share price has seen a 13.7% decline over the past week and a 16.7% decline over the last 30 days, even though the 1 year return sits at 39.2% and the 3 year return at 50.8%. This mix of shorter term weakness and longer term gains can sometimes reflect shifting views on risk and potential, especially for a biotech where sentiment often turns quickly...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 13, 2026

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 11 Best Day Trading Stocks to Buy Now. Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 13, 2026

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 13, 2026

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Moby
Mar 13, 2026

Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary

Moby summary of Mineralys Therapeutics, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.